Our survival analyses in the 135 GC patients with stage IB to IV tumors revealed that both ATG-5 and MRP-1 expression were able to independently predict the OS and DFS after treatment with adjuvant ECF chemotherapy, suggesting that monitoring their expression levels in combination of conventional prognostic markers may provide us with additional valuable information for a better evaluation of chemotherapy effect in GC patients. This evidence concerns the gene ABCC1 and gastric cancer.